Bioliberty raises €2.95 million to bring its AI-powered rehabilitation technology into the home

The round saw participation from four new investors: TGH Ventures, the investment arm of Tampa General Hospital, Ballad Ventures, Belfast-based Whiterock and 25m Health. The company had previously raised €9.12 million ($10.2 million) through its pre-Series A and Series A rounds.

“This funding and our new strategic investors are crucial to our next phase: creating a more connected rehabilitation journey. We want to connect data across the patient journey, extend our technology into the home, and use AI to further augment therapy and assessment for physical and occupational therapists,” said Rowan Armstrong, co-founder and CEO of Bioliberty.

Bioliberty was founded in 2020 by Armstrong, Ross O’Hanlon, Conan Bradley and Shéa Quinn, all from Northern Ireland. The company develops robotic rehabilitation technology to help patients recover hand and arm movement after strokes or other neurological conditions.

Its product includes three main components: Lifehub, a portable device that runs therapy sessions; Lifeglove, a soft robotic glove that helps patients open and strengthen their hands and Lifemind, a dashboard that helps doctors track therapy progress and prepare clinical notes using AI. Lifehub and Lifeglov are FDA-listed in the US, where the company launched its products commercially in 2025.

Bioliberty says its technology was developed with rehabilitation centres. It allows therapy sessions to start in under five minutes and helps patients complete more exercises during each session.

“Bioliberty has been implemented by our therapists seamlessly. Patients are excited to see gains in their function and enjoy the interactivity of the tasks and games they can access,” said Ethan Clark, Therapy Manager, Methodist Rehabilitation Hospital.

Read More:Alethio Therapeutics raises €80.46 million Series A to advance targeted blood cancer therapies